Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 2;48(W1):W488-W493.
doi: 10.1093/nar/gkaa216.

SynergyFinder 2.0: visual analytics of multi-drug combination synergies

Aleksandr Ianevski  1   2 , Anil K Giri  1 , Tero Aittokallio  1   2   3   4
Affiliations

SynergyFinder 2.0: visual analytics of multi-drug combination synergies

Aleksandr Ianevski et al. Nucleic Acids Res. .

Erratum in

Abstract

SynergyFinder (https://synergyfinder.fimm.fi) is a stand-alone web-application for interactive analysis and visualization of drug combination screening data. Since its first release in 2017, SynergyFinder has become a widely used web-tool both for the discovery of novel synergistic drug combinations in pre-clinical model systems (e.g. cell lines or primary patient-derived cells), and for better understanding of mechanisms of combination treatment efficacy or resistance. Here, we describe the latest version of SynergyFinder (release 2.0), which has extensively been upgraded through the addition of novel features supporting especially higher-order combination data analytics and exploratory visualization of multi-drug synergy patterns, along with automated outlier detection procedure, extended curve-fitting functionality and statistical analysis of replicate measurements. A number of additional improvements were also implemented based on the user requests, including new visualization and export options, updated user interface, as well as enhanced stability and performance of the web-tool. With these improvements, SynergyFinder 2.0 is expected to greatly extend its potential applications in various areas of multi-drug combinatorial screening and precision medicine.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
SynergyFinder 2.0 visual analytic options for (A) pairwise combinations and (B) higher-order combinations. (C) 3D synergy landscapes shown separately for each two-drug sub-combination.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Davies G., Boeree M., Hermann D., Hoelscher M.. Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: new technologies and innovative designs. PLoS Med. 2019; 16:e1002851. - PMC - PubMed
    1. Adam I., Ibrahim Y., Gasim G.I.. Efficacy and safety of artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Sudan: a systematic review and meta-analysis. Malar. J. 2018; 17:110. - PMC - PubMed
    1. Properzi M., Magro P., Castelli F., Quiros-Roldan E.. Dolutegravir-rilpivirine: first 2-drug regimen for HIV-positive adults. Expert Rev. Anti Infect. Ther. 2018; 16:877–887. - PubMed
    1. Sun W., He S., Martinez-Romero C., Kouznetsova J., Tawa G., Xu M., Shinn P., Fisher E., Long Y., Motabar O. et al. .. Synergistic drug combination effectively blocks Ebola virus infection. Antiviral Res. 2017; 137:165–172. - PMC - PubMed
    1. Gotwals P., Cameron S., Cipolletta D., Cremasco V., Crystal A., Hewes B., Mueller B., Quaratino S., Sabatos-Peyton C., Petruzzelli L. et al. .. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat. Rev. Cancer. 2017; 17:286–301. - PubMed

Publication types